What is a stock summary page? Click here for an overview.
Business Description
Aurobindo Pharma Ltd
ISIN : INE406A01037
Share Class Description:
NSE:AUROPHARMA: Ordinary SharesCompare
Compare
Traded in other countries / regions
AUROPHARMA.India Index Membership
NIFTY 500iShares MSCI ACWI Ex US Index Fund IPO Date
2000-07-19Description
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.89 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | 1.22 | |||||
| Interest Coverage | 12.22 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.67 | |||||
| Beneish M-Score | -2.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.3 | |||||
| 3-Year EBITDA Growth Rate | -10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 4.4 | |||||
| 3-Year Book Growth Rate | 10.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.06 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.21 | |||||
| 9-Day RSI | 62.79 | |||||
| 14-Day RSI | 60.54 | |||||
| 3-1 Month Momentum % | -1.42 | |||||
| 6-1 Month Momentum % | -16.33 | |||||
| 12-1 Month Momentum % | 8.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.83 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 270.22 | |||||
| Days Sales Outstanding | 59.24 | |||||
| Days Payable | 122.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.02 | |||||
| 3-Year Dividend Growth Rate | 4 | |||||
| Shareholder Yield % | -2.31 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.4 | |||||
| Operating Margin % | 16.43 | |||||
| Net Margin % | 11.45 | |||||
| FCF Margin % | -3.7 | |||||
| ROE % | 11.78 | |||||
| ROA % | 7.64 | |||||
| ROIC % | 10.51 | |||||
| 3-Year ROIIC % | -0.96 | |||||
| ROC (Joel Greenblatt) % | 22.79 | |||||
| ROCE % | 16.52 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.63 | |||||
| Forward PE Ratio | 16.54 | |||||
| PE Ratio without NRI | 19.93 | |||||
| Shiller PE Ratio | 19.47 | |||||
| Price-to-Owner-Earnings | 46.83 | |||||
| PEG Ratio | 6.64 | |||||
| PS Ratio | 2.36 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 2.64 | |||||
| Price-to-Operating-Cash-Flow | 29.7 | |||||
| EV-to-EBIT | 13.36 | |||||
| EV-to-Forward-EBIT | 6.47 | |||||
| EV-to-EBITDA | 10.4 | |||||
| EV-to-Forward-EBITDA | 4.86 | |||||
| EV-to-Revenue | 2.35 | |||||
| EV-to-Forward-Revenue | 0.88 | |||||
| EV-to-FCF | -61.19 | |||||
| Price-to-GF-Value | 1.12 | |||||
| Price-to-Projected-FCF | 2.14 | |||||
| Price-to-DCF (Earnings Based) | 1.77 | |||||
| Price-to-Median-PS-Value | 1.03 | |||||
| Price-to-Graham-Number | 1.5 | |||||
| Price-to-Net-Current-Asset-Value | 7.87 | |||||
| Earnings Yield (Greenblatt) % | 7.49 | |||||
| FCF Yield % | -1.6 | |||||
| Forward Rate of Return (Yacktman) % | -0.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aurobindo Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 304,889.3 | ||
| EPS (TTM) (₹) | 59.81 | ||
| Beta | 1.25 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 0.82 | ||
| Volatility % | 32.22 | ||
| 14-Day RSI | 60.54 | ||
| 14-Day ATR (₹) | 44.625856 | ||
| 20-Day SMA (₹) | 1145.9975 | ||
| 12-1 Month Momentum % | 8.3 | ||
| 52-Week Range (₹) | 1010 - 1592 | ||
| Shares Outstanding (Mil) | 580.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurobindo Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurobindo Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aurobindo Pharma Ltd Frequently Asked Questions
What is Aurobindo Pharma Ltd(NSE:AUROPHARMA)'s stock price today?
The current price of NSE:AUROPHARMA is ₹1220.10. The 52 week high of NSE:AUROPHARMA is ₹1592.00 and 52 week low is ₹1010.00.
When is next earnings date of Aurobindo Pharma Ltd(NSE:AUROPHARMA)?
The next earnings date of Aurobindo Pharma Ltd(NSE:AUROPHARMA) is .
Does Aurobindo Pharma Ltd(NSE:AUROPHARMA) pay dividends? If so, how much?
Aurobindo Pharma Ltd(NSE:AUROPHARMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers